Trials / Unknown
UnknownNCT03178188
Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus
Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Chulalongkorn University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
forty DLE lesions from patients will be recruited in the study. The lesions on one side of the body were block-randomized into the treatment group and the other side served as a control. The patients can continue their systemic treatments and the PDL is designed to be used as an adjunctive treatment. Treatments with the PDL will be delivered in the treatment group every 4 weeks for 4 consecutive months while the lesions in the control group received a sham. The patients will be evaluated at baseline (week 0), week 4, 8, 12, and at follow-up period of 4, 12 weeks after the final treatment (week 16, 24). Erythema index (EI), Texture index (TI) will be obtained and digital photographs will be taken and modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI) will be assessed in every visit. The digital photographs will later be evaluated by 3-blinded dermatologists. Moreover, side effects and patients' satisfaction score will also be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Pulsed-dye Laser | 595 nm Pulsed-dye Laser; 7mm spot sizes, 6msec pulse durations, 8j/cm2 fluences, dynamic cooling device 30/20, 4 sessions with 4 weeks interval |
| DEVICE | Sham | Cryogen spray with the setting of dynamic cooling device 30/20 |
Timeline
- Start date
- 2016-12-15
- Primary completion
- 2017-12-14
- Completion
- 2017-12-14
- First posted
- 2017-06-06
- Last updated
- 2017-06-06
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03178188. Inclusion in this directory is not an endorsement.